בס״ד

HARMaceutical Giant Eli Lilly takes a Dip (LLY)

Posted on April 19, 2023

This week’s A Jew and His Gold is coming at you early to take advantage of a special opportunity in the big pharma sub-sector.

It wasn’t so long ago we played Eli Lilly (NYSE:LLY) for healthy profits, and today we’re lining up to do the same.

For those who don’t know, the crime family that operates LLY is in the ostensibly legitimate business of maiming and killing human beings with its broad line of harmaceuticals.

Fundamentally, the old gal’s a bit out of whack—

  • P/E is an immodest 53.53, while…
  • Dividend Yield is an embarrassing 1.22%.
  • Price to Book is a drunkard-like 31.32 (!), and…
  • Debt to Equity is loaded at 1.52.
  • Finally, latest Q/Q Sales FELL 8.70%.

All told, not a report card to kvell over.

Have a look at the chart—

May the Holy One decide in our favor.

Many happy returns!

Matt McAbby

 

Leave a Reply

Your email address will not be published. Required fields are marked *